On June 25, at the Mishui Pharmaceutical and Health Industry Symbiosis Conference held in Huzhou, Zhejiang, the high-profile "2023 Top 100 Chinese Pharmaceutical Industry Series List" was officially announced.
Jiuhua Huayuan Pharmaceutical stood out in this selection and ranked 86th in the TOP100 list of Chinese traditional Chinese medicine enterprises, up two places from last year, demonstrating its steady growth momentum.
The list is subdivided into five sub-lists, including "Top 100 Chinese Chemical Pharmaceutical Enterprises", "Top 100 Chinese Medicine Enterprises", and "Top 20 Chinese CXO Enterprises". The selection is based on the database of three terminals and six major market terminals exclusively developed and operated by Minenet for many years, and comprehensively evaluates pharmaceutical industry enterprises from the two key dimensions of "innovation driving force" and "professional promotion force". Jiuhua Huayuan Pharmaceutical Co., Ltd. has been highly recognized by the industry for its excellent innovation ability and professional promotion ability.
At the same time, the meeting announced the "China Pharmaceutical Brand List", and Jiuhua Huayuan Pharmaceutical's star product Bairui ® Granules was impressively listed. In the prevention and treatment of new crown pneumonia, influenza, Mycoplasma pneumonia in children and other diseases over the years, Bairui granules have played a major therapeutic role, which is the value of brand power.
In 2023, Jiuhua Huayuan Pharmaceutical will not only consolidate the market position of its core products, but also increase the research and development and promotion of new products. Its flagship product, Baikang Ling ® Zhenyuan Tablets, won the bid with a significant price advantage and quickly entered the clinical market, providing a better treatment option for patients with cardiovascular and cerebrovascular diseases. At the same time, the company's exclusive products Anssokang Granules and Yuye Jinhua Qingre Tablets also occupy an important position in the pediatric and respiratory markets.
Jiuhua Huayuan Pharmaceutical's strength in research and development should not be underestimated, up to now, the company has more than 30 products under development, and holds 53 national patents. Technological innovation platforms such as postdoctoral research workstations and provincial enterprise technology centers provide a solid foundation for the company to introduce, digest, absorb and re-innovate advanced technologies at home and abroad.
In order to further enhance its competitiveness, Jiuhua Huayuan Pharmaceutical Co., Ltd. has continued to increase investment in R&D, continuously introduced and cultivated high-end talents, and built a professional R&D team. At the same time, the company also actively establishes cooperative relations with well-known scientific research institutions and universities at home and abroad to jointly carry out new drug research and development and technological innovation, injecting a steady stream of power into the company's sustainable development.
In terms of marketing, Jiuhua Huayuan Pharmaceutical has also shown strong strength. The company actively expands sales channels and has established close cooperative relations with major medical institutions and pharmacies, so that the products can quickly cover the market. In addition, the company also pays attention to brand building and publicity, and enhances brand influence and market competitiveness through various pharmaceutical exhibitions and academic seminars.
In the future, Jiuhua Huayuan Pharmaceutical will continue to adhere to the development concept of "steady loyalty, innovation mileage", and continuously improve its R&D strength and market competitiveness. The company will continue to increase investment, expand new business areas, and promote the company's development to a higher level, wider field and deeper level. At the same time, Jiuhua Huayuan Pharmaceutical will also actively fulfill its social responsibilities and contribute more to the cause of human health.